146 results on '"Sahin, Ozgur"'
Search Results
2. HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer
3. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
4. Continuously tracked, stable, large excursion trajectories of dipolar coupled nuclear spins
5. A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer
6. Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response
7. Transcriptome analysis of polyploid giant cancer cells and their progeny reveals a functional role for p21 in polyploidization and depolyploidization
8. Hydration solids
9. Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
10. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification
11. Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis
12. Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer
13. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin
14. High field magnetometry with hyperpolarized nuclear spins
15. TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness
16. Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
17. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
18. Cholesterol biogenesis is a PTEN‐dependent actionable node for the treatment of endocrine therapy‐refractory cancers
19. Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer
20. Research on perinatal Cytomegalovirusinfections: Bibliometric Analysis (1990–2022)
21. Can Stria Gravidarum Predict Surgical Fluid Loss in Cesarean Section?
22. TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness.
23. A novel prenatal index predicting the probability of neonatal intensive care in pregnants: amnion progesterone receptor to alfa fetoprotein rate
24. Abstract 5728: Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification
25. Abstract 3883: Overcoming tamoxifen resistance by re-activating cAMP-Ca2+−ROS-ferroptosis axis in ER+ breast cancer
26. Abstract 578: Novel bi-thiazole LOX inhibitors to overcome chemotherapy resistance in triple negative breast cancer
27. Figure S1 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
28. Supplementary Tables from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
29. Supplementary Data from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
30. Table S2 from Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors
31. Supplementary Figures from Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells
32. Figure S1-11 from Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors
33. Supplementary Table from Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells
34. Data from Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells
35. Data from 14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation
36. Supplementary Figure 2 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
37. Supplementary Figure 7 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
38. Supplementary Figure 3 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
39. Supplementary Figure 4 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
40. Supplementary Figure 9 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
41. Supplementary Tables 1 - 4 from 14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation
42. Supplementary Figure 1 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
43. Supplementary Figure 8 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
44. Supplementary Table 1 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
45. Supplementary Figure Legends 1-9 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
46. Supplementary Figure 5 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
47. Supplementary Methods from 14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation
48. Supplementary Figures 1 - 7 from 14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation
49. Supplementary Figure 6 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
50. Abstract P6-10-18: Developing novel lysyl oxidase (LOX) inhibitors to overcome chemotherapy resistance in triple negative breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.